卵巣がん診断の市場規模、シェア、成長分析、がんタイプ別、検査タイプ別、地域別 - 産業予測、2025～2032年

卵巣がん診断の世界市場規模は、2023年に19億米ドルと評価され、予測期間（2025-2032年）のCAGRは5.4%で、2024年の20億米ドルから2032年には30億5,000万米ドルに成長する見通しです。

卵巣がん、特に上皮性卵巣がんは重大な健康問題であり、世界の女性のがん関連死亡原因の第5位を占めています。卵巣がん診断薬市場の急増は、革新的な治療法、がん研究への資金提供の増加、健康意識の高まり、高齢女性の人口増加など、いくつかの要因によってもたらされています。診断技術の進歩は、早期発見を強化する新たな機会を提供します。現在、進行した段階でのみ病気を特定する傾向がある既存の方法には大きなギャップがあります。さらに、便利でタイムリーな診断ソリューションを開発するための政府や機関の取り組みも、市場の成長には欠かせません。このようなエコシステムは、卵巣がんの早期発見と治療成績の大幅な改善の可能性を強調するものです。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制分析
• ケーススタディ分析

卵巣がん診断市場規模：がんタイプ別

• 市場概要
• 上皮性腫瘍の診断
• 胚細胞がんの腫瘍診断
• 間質がんの腫瘍診断
• その他

卵巣がん診断市場規模：検査タイプ別

• 市場概要
• イメージング
  • 超音波
• CTスキャン
• MRIスキャン
• PETスキャン
  • その他
• 血液検査
• CA125
• HER2
• BRCA
• インド原子力庁
• ERとPR
• KRAS変異
  • その他
• 生検
• その他

卵巣がん診断市場規模：エンドユーザー別

• 市場概要
• 病院関連ラボ
• 独立診断研究所
• がん調査機関
• その他

卵巣がん診断市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
• 収益の前年比比較（2022-2024）

主要企業プロファイル

• Illumina
• Thermo Fisher Scientific
• Roche
• Siemens Healthineers
• Abbott
• QIAGEN
• Hologic
• Beckman Coulter
• Becton, Dickinson and Company（BD）
• Bio-Rad Laboratories
• Quest Diagnostics
• Myriad Genetics
• Genomic Health（Exact Sciences）
• Agilent Technologies
• PerkinElmer Inc.
• bioMerieux SA
• Merck KGaA
• GE Healthcare
• Sysmex Corporation
• NanoString Technologies

結論と推奨事項

Global Ovarian Cancer Diagnostic Market size was valued at USD 1.9 billion in 2023 and is poised to grow from USD 2 billion in 2024 to USD 3.05 billion by 2032, growing at a CAGR of 5.4% during the forecast period (2025-2032).

Ovarian cancer, particularly epithelial ovarian cancer, is a significant health concern and the fifth leading cause of cancer-related death among women globally. The surge in the ovarian cancer diagnostics market is driven by several factors, including innovative treatment modalities, increased funding for cancer research, heightened health awareness, and a growing population of older women. Advancements in diagnostic technologies present new opportunities to enhance early detection, currently a major gap in existing methods that tend to identify the disease only at advanced stages. Additionally, government and institutional efforts to develop convenient and timely diagnostic solutions are crucial for market growth. This ecosystem underscores the potential for significant improvements in early detection and treatment outcomes in the ovarian cancer landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ovarian Cancer Diagnostic market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ovarian Cancer Diagnostic Market Segmental Analysis

Global Ovarian Cancer Diagnostic Market is segmented by cancer type, test type, end user and region. Based on cancer type, the market is segmented into epithelial tumor diagnostics, germ cell carcinoma tumor diagnostics, stromal carcinoma tumor diagnostics and others. Based on test type, the market is segmented into imaging, blood test, biopsy and others. Based on end user, the market is segmented into hospital associated labs, independent diagnostic laboratories, cancer research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ovarian Cancer Diagnostic Market

The Global Ovarian Cancer Diagnostic market is being significantly propelled by the increasing population of elderly women, which correlates with a higher incidence of ovarian cancer cases. This demographic shift is prompting governments to enhance healthcare initiatives aimed at cancer detection and treatment. Moreover, rising healthcare awareness among individuals is contributing to market expansion, as more patients seek diagnostic solutions and innovative treatments, including established drugs like Bevacizumab (Avastin) and Pazopanib (Votrient). Concurrently, the expiration of patents for existing medications is paving the way for new entrants into the market and stimulating the adoption of innovative combination therapies. Additionally, ongoing research and development, supported by both governmental and private funding, further enrich the market landscape, creating opportunities for advancements in ovarian cancer diagnostics and treatments.

Restraints in the Global Ovarian Cancer Diagnostic Market

One significant restraint affecting the global ovarian cancer diagnostic market is the widespread ignorance surrounding the symptoms of ovarian cancer. Often, these symptoms are overlooked or misdiagnosed, as they can easily be mistaken for those associated with other medical conditions. This lack of awareness leads to delayed detection and diagnosis, severely impacting treatment outcomes. As a result, the progression of ovarian cancer can worsen, complicating the clinical management of the disease. Ultimately, this scenario not only hinders patient outcomes but also impacts market growth, as timely diagnosis and treatment are crucial for effective management of ovarian cancer.

Market Trends of the Global Ovarian Cancer Diagnostic Market

The global ovarian cancer diagnostic market is witnessing a significant upward trend driven by the growing understanding of cancer biomarkers and advancements in detection technologies. Enhanced biotechnological innovations have facilitated the identification and commercialization of potential biomarkers, creating new avenues for effective diagnosis and treatment of ovarian cancer. This surge in biomarker research, coupled with improved diagnostic equipment, is empowering healthcare providers with tools for early detection, thus enhancing patient outcomes. As a result, the market is poised for substantial growth as stakeholders invest in the development and implementation of novel diagnostic solutions to meet the rising demand for precision oncology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Case Study Analysis

Global Ovarian Cancer Diagnostic Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Epithelial Tumor Diagnostics
• Germ Cell Carcinoma Tumor Diagnostics
• Stromal Carcinoma Tumor Diagnostics
• Others

Global Ovarian Cancer Diagnostic Market Size by Test Type & CAGR (2025-2032)

• Market Overview
• Imaging
  • Ultrasound
• CT Scan
• MRI Scan
• PET Scan
  • Others
• Blood Test
• CA125
• HER2
• BRCA
• CEA
• ER & PR
• KRAS Mutation
  • Others
• Biopsy
• Others

Global Ovarian Cancer Diagnostic Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital Associated Labs
• Independent Diagnostic Laboratories
• Cancer Research Institutes
• Others

Global Ovarian Cancer Diagnostic Market Size & CAGR (2025-2032)

• North America (Cancer Type, Test Type, End User)
  • US
  • Canada
• Europe (Cancer Type, Test Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Test Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Test Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Test Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
• Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Illumina
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genomic Health (Exact Sciences)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoString Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations